Skip to content
MARKETS / NASDAQ / TVTX
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Travere Therapeutics, Inc. TVTX

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$490.7M
▲ 110.5% YoY
$-25.5M
In brief

What this company does

Travere Therapeutics, Inc. commercializes its products in the United States with a specialty sales force. FILSPARI (sparsentan) is indicated to slow kidney function decline in adults with primary Immunoglobulin A nephropathy who are at risk of disease progression. Thiola and Thiola EC are approved by the FDA for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company is headquartered in San Diego, California. As of January 31, 2026, the company had 497 full-time employees, with most based in the United States and a small number outside of the United States. The company was incorporated in the state of Delaware in February 2011.

Written from the business description in Travere Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.

Growth
USD 490.7M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 490.7 · Net income -25.5
200M400M-200M201020122014201620182020202220242025
Compound annual growth
+64.9%
+19.9%
+17.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +19.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−5 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -12.8% · Net -5.2%
50%100%-100%-200%-300%201020122014201620182020202220242025
ROE
FY2025 · ROE -29.4%
50%-100%-200%201020122014201620182020202220242025

Each USD of equity lost 29 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -280.7
-100M-200M201020122014201620182020202220242025
Net buybacks $M Dividends $M
FY2016 · Dividends — · Net buybacks -4.0
-50M-100M2013201420152016

Total assetsUSD 605.2M
EquityUSD 114.8M
CashUSD 93.0M
Current ratio2.74×

Equity funds 19% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.50.20.10.10.10.20.20.20.20.10.10.00.0·0.00.0
Operating income $B−0.1−0.3−0.4−0.3−0.2−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0··
EBITDA $B−0.0−0.3−0.3−0.3−0.2−0.2−0.1−0.1−0.0−0.0−0.0−0.1−0.0−0.0··
Income tax $B0.00.00.00.00.0−0.0−0.00.00.0−0.0−0.0−0.00.0···
Net income $B−0.0−0.3−0.1−0.3−0.2−0.2−0.1−0.1−0.1−0.00.1−0.1−0.0−0.0−0.0−0.0
Free cash flow $B··−0.3−0.2−0.0−0.0−0.1−0.00.0−0.0−0.0−0.0−0.0−0.0··
EPS, diluted $−0.29−4.08−1.50−4.37−3.01−3.56−3.46−2.54−1.54−1.293.17−4.43−2.44−8.29··
Dividend / sh $················
Payout %················
ROE %−29.4−247.4−91.4−161.5−70.2−78.4−54.3−33.6−19.9−15.889.2·····
Shares out B0.090.090.080.060.060.050.040.040.040.040.040.030.020.01··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 22 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inCalifornia
Fiscal year endsDecember 31
Data on record since2010

Share this section

Download image